Exelixis | EXEL - أسهم رأس المال العادية





أسهم رأس المال العادية تغيير تاريخ
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
Amgen USD 541M 1000K 2026-06
AstraZeneca USD 1.55B 28K 2026-09
Bayer EUR 982.42M 0 2026-06
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Bristol-Myers Squibb USD 2.04B 7M 2026-06
Cytokinetics USD 124.43M 2.17M 2026-03
Eisai JPY 282.46M 345K 2026-06
Eli Lilly USD 943.5M 3.33M 2026-03
Exelixis USD 244.68M 4.21M 2026-09
Genmab DKK 61.44M 181K 2026-06
Glaxosmithkline GBP 2.02B 2.03B 2026-09
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
MacroGenics USD 63.65M 86K 2026-06
Merck USD 2.47B 1.05M 2026-06
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 101.3M 750K 2026-09
Novartis USD 1.89B 12.09M 2026-09
Pfizer USD 5.7B 0 2026-06
Puma Biotechnology USD 5K 0 2024-06
Sanofi EUR 1.2B 2.15M 2026-06
Takeda JPY 1.58B 460K 2026-06
Ultragenyx Pharmaceutical USD 98.6M 300K 2026-06
Xencor USD 74.33M 265K 2026-06